Compare Johnson & Johnson (JNJ) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Taskus Inc — how do they compare? Johnson & Johnson trades at $259.62 (market cap $618.09B), while Taskus Inc trades at $8.09 (market cap $723.41M). The key difference: Johnson & Johnson is far larger — about 854.4× Taskus Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Taskus Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Taskus Inc for 34 Days on average.
| JNJ | TASK | |
|---|---|---|
Market Cap | $618.09B | $723.41M |
Volume | 6,050,983 | 201,303 |
Sector | Health | Technology |
52-Week High | $278.43 | $14.69 |
52-Week Low | $186.00 | $4.57 |
Typical Hold Time | 129 Days | 34 Days |
Enterprise Value | $646.37B | $1.09B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
TaskUs (TASK) trades at $8.06, up 2.15% today, with a bearish technical signal but strong fundamentals. Revenue reached $1.18 billion in 2025, with net income surging to $102.28 million and an 8.75% margin. The stock appears undervalued with a P/E of 6.8 and P/S of 0.6. Recent news highlights AI-driven growth offsetting legacy declines, with Q2 2026 earnings beating estimates.
The outlook is mixed: low valuation and AI expansion offer upside, but technical weakness and margin pressure from labor costs pose risks. Analysts are generally bullish with a $9.33 consensus target, implying 16% upside, though competitive and execution challenges remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
